Skip to main content
Download PDF

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro

Stem Cell Research & Therapy volume 13, Article number: 299 (2022) Cite this article

A Correction to this article was published on 25 November 2022

This article has been updated

Abstract

Background

Most castration-resistant prostate cancers (CRPCs) have a luminal phenotype with high androgen receptor (AR) and prostate-specific antigen (PSA) expression. Currently, it is difficult to culture castration-resistant luminal cells with AR and PSA expression.

Methods

We formulated a custom-made medium and isolated primary cells from the prostate of adult wild-type (WT) and TRAMP mice. The cells were characterized by immunofluorescence staining, transcriptomic analysis, and qRT-PCR verification. Their self-renewal and differentiation potential in vitro and in vivo were examined. We treated the cells with androgen deprivation and enzalutamide and performed immunofluorescence staining and western blotting to analyze their expression of AR and PSA.

Results

We isolated a novel type of castration-resistant intermediate prostate stem cells (CRIPSCs) from adult WT and TRAMP mice. The mouse CRIPSCs proliferated rapidly in two-dimensional (2D) culture dishes and can be cultured for more than six months. The mouse CRIPSCs expressed luminal markers (AR, PSA, and Dsg4), basal markers (CK5 and p63), Psca, and the intermediate cell marker (Ivl). Transcriptomic analysis showed that the mouse CRIPSCs had upregulated signaling pathways related to cancer development and drug resistance. In the long-term culture, TRAMP CRIPSCs had higher expression of the genes related to stem cells and cancers than WT mice. Both WT and TRAMP CRIPSCs formed organoids in Matrigel. WT CRIPSCs did not form prostate tissues when transplanted in vivo without urogenital sinus mesenchyme (UGM) cells. In contrast, TRAMP CRIPSCs formed prostate ducts in NOG mice without UGM  cells and differentiated into luminal, basal, and neuroendocrine cells. Androgens regulated AR translocation between the nucleus and cytoplasm in the mouse CRIPSCs. Treatment of androgen deprivation  (ADT) and enzalutamide reduced AR expression in WT and TRAMP CRIPSCs; however, this treatment promoted PSA expression in TRAMP, while not WT CRIPSCs, similar to the clinical observations of CRPC.

Conclusions

Our study established a method for isolating and expanding mouse CRIPSCs in 2D culture dishes. Mouse CRIPSCs had markers of basal and luminal cells, including AR and PSA, and can differentiate into prostate organoids and tissues. TRAMP CRIPSCs had elevated PSA expression upon ADT and enzalutamide treatment. Our method can be translated into clinical settings for CRPC precision medicine.

Background

Prostate cancer is the second most cancer type in men globally. It is commonly diagnosed by the level of prostate-specific antigen (PSA), which is regulated by androgen receptor (AR). AR is the major transcription factor regulating prostate development and plays a crucial role in prostate cancer [1,2,3]. Androgen deprivation therapy (ADT) is the most common first-line treatment for prostate cancer [4]. Tumor mass and AR expression will regress temporarily after ADT treatment; however, most patients will eventually develop castration-resistant prostate cancer (CRPC) and re-acquire high levels of AR and PSA [1, 5]. Thus, the AR signaling pathway is the main target for next-generation therapies [6]. For example, abiraterone and enzalutamide are two new approved drugs targeting androgen synthesis and AR, respectively [5]. They showed some improvement although the patients will inevitably develop drug resistance after a few months [5, 7, 8]. Currently, CRPC is incurable [5].

A central question in CRPC research is to find out the cellular origins of castration resistance. There are adult stem cells in the basal and luminal layers of the prostate [9,10,11,12,13]. By immunohistological studies on animal tissues, it has been well characterized that there are castration-resistant prostate stem cells, which are potential candidates for the cellular origins of CRPC [9]. Upon androgen deprivation by chemical or surgical castration, most prostate luminal epithelial cells will die; however, re-administration of androgens will regenerate the entire prostate tissues again, implying the existence of castration-resistant prostate stem cells [9]. Wang et al. identified a small number (0.7%) of castration-resistant Nkx3.1-expressing cells (CARNs) in the luminal compartment of the mouse prostate [14]. CARNs express luminal markers CK18 and AR and can differentiate into luminal, basal, and neuroendocrine cells when transplanted into immunodeficient mice in combination with urogenital mesenchymal (UGM) cells [14]. Yoo et al. found another type of castration-resistant Bmi1-expressing cells (CARBs) located in the luminal layer [15, 16]. CARBs also express luminal markers CK8, AR, and stem cell marker Sox2 and can differentiate into the three prostate lineages [15, 16]. Kwon et al. identified Sca-1+CK8+AR+ luminal cells from castrated mouse prostate and found that they can differentiate into the luminal and basal cells when transplanted in immunodeficient mice in combination with UGM cells [17]. The pulse-chase method with bromodeoxyuridine has identified quiescent label-retaining luminal stem cells expressing AR in the prostate [18]. To locate castration-resistant stem cells unbiasedly, Zhang et al. adopted a tet-off system to chase label-retaining dormant stem cells during mouse castration [19]. They found the castration-resistant label-retaining stem cells in the luminal layer and expressed luminal markers, including AR, CK8, CK18, Nkx3.1, Pbsn, and the intermediate marker CK19 [19].

In vitro culture models provide valuable tools for prostate cancer research. There have been some methods for culturing prostate basal or luminal stem cells [20, 21]. The development of precision medicine for CRPC requires isolating and expanding patient-specific castration-resistant cells expressing luminal markers, including AR and PSA. There are reports about culturing patient-derived three-dimensional (3D) organoids from prostate tissues. The 3D organoids are composed of luminal and basal cells and are sensitive to androgen deprivation [22,23,24]. Two-dimensional (2D) culture is convenient for most laboratories. Zhang et al. established a 2D culture system for expanding luminal progenitor cells expressing AR, PSA, and CK18 [20]. The cultured prostate cells can be genetically modified to mimic tumor formation [20, 25]. These cultured luminal cells are still sensitive to ADT in vitro.

This study aimed to establish a method for in vitro expanding prostate luminal stem cells that can resist ADT and express AR and PSA, which will benefit CRPC research. Our previous study established a method to expand adult epithelial progenitor cells from mouse lens epithelium [26]. We found that TGFβ/Smad inhibition was necessary for maintaining adult epithelial identity in vitro. The addition of growth factors (e.g., bFGF) promoted cell proliferation; however, it led to the differentiation and loss of epithelial identity [26]. In addition, ROCK inhibitor Y27632 can promote cell survival [27] and prostate epithelial cell expansion in vitro [20]. The Wnt/β-catenin signaling pathway plays an essential role in prostate development and cancer [28, 29]. Thus, in this study, we formulated a custom-made medium containing TGFβ/Smad inhibitor (A83-01), ROCK inhibitor (Y27632), Wnt/β-catenin pathway agonist (Chir99021), and 10 nM dihydrotestosterone (DHT), without any growth factors. We succeeded in expanding a novel type of castration-resistant intermediate prostate stem cells (CRIPSCs) from wild-type (WT) and TRAMP mice in vitro. They expressed luminal cell markers (AR and PSA), basal cell markers (p63 and CK5), E-cadherin, prostate stem cell antigen (Psca), and intermediate cell marker involucrin (Ivl). Upon androgen deprivation and enzalutamide treatment, TRAMP CRIPSCs showed reduced AR expression while elevated PSA levels, similar to the clinical observations of CRPC.

Methods

Primary cell isolation and culture

The TRAMP mice (Jax#003135) were purchased from The Jackson Laboratories (USA). Genotyping of the TRAMP mice was performed according to the protocol provided by The Jackson Laboratory. WT C57BL/6 J mice were purchased from Ji’nan Pengyue Laboratory Animal Breeding Co., Ltd (China). Primary mouse prostate cells were isolated from the prostate tissues of male WT C57BL/6 J and TRAMP mice of 2–3 months. The cyclic digestion method was used to isolate primary cells. Briefly, mouse prostate tissues, including anterior, ventral, and dorsolateral lobes, were digested in the enzymatic solution containing 2 mg/ml Collagenase I, 2 mg/ml Dispase, 5 mg/ml BSA, and 5 μM Y27632 in DMEM at 37 °C. The cell suspension was collected every 10 min and centrifuged at 1000 rpm for 4 min, and the pellet was re-suspended in PBS. The fresh enzymatic solution was added to the remaining tissues for further treatment until all the tissue pieces were digested. Subsequently, all the cell suspensions were pooled together, centrifuged, and re-suspended in a custom-made prostate cell culture medium containing DMEM/F12 (Invitrogen, Cat# 12,400,024, USA), 2% fetal bovine serum (FBS, Gibco, Cat#10,091,148, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, Cat#15,140,122, USA), 5 mM nicotinamide (Sigma, Cat#N0636, USA), 1 mM NAC (Sigma, Cat#A9165, USA), 50 μM Vitamin C (Sigma, Cat#A4403, USA), 3 μM glutathione (Sigma, Cat#G6013, USA), 10 μg/ml insulin (Aladdin, Cat#I113907, China), 7.5 μg/ml transferrin (Sigma, Cat#T0665, USA), 40 nM Sodium Selenite (Sigma, Cat#S9133, USA), 1 μM PGE2, 2 μM Chir99021 (Sellect, Cat#S2924, China), 0.2 μM A83-01 (Tocris, Cat#2939, UK), and 5 μM Y27632 (Sellect, Cat#S1049, China).

Before cell seeding, the culture dishes were incubated with 0.1 mg/ml Matrigel solution diluted in DMEM for one hour and washed with PBS. Accutase (Gibco, Cat#A1110501, USA) was used for cell passaging. During the early four or five passages, the primary cells grew slowly and were passaged at a ratio of 1:1. Many cells died during this period. After P5, i.e., about two months of culture in vitro, we obtained a relatively uniform population of epithelial cells with a high proliferation rate. The split ratio can be 1:20 or more during passaging. 2 × 104 cells can grow to over 106 in a week, with a doubling time of about one day.

Histology and immunostaining

The cultured cells were fixed in 4% paraformaldehyde (PFA) for 20 min, washed with PBS, permeabilized in 0.1% Triton X-100 for 10 min, and blocked with 5% normal donkey serum for 1 h. Primary antibodies diluted in 5% normal donkey serum and 0.1% Triton X-100 in PBS were added and incubated at 4 °C overnight. Primary antibodies used in this study included: anti-E-cadherin antibody (1:200, 20874-1-AP, Proteintech, China), anti-CK5 antibody (1:100, D220236, Sangon Biotech, China), anti-CK8 antibody (1:100, D220230, Sangon Biotech, China), anti-CK18 antibody (1:200, 66187-1-Ig, Proteintech, China), anti-SOX2 antibody (1:100, 11064-1-AP, Proteintech, China), anti-AR antibody (1:500, ab108341, Abcam, USA), anti-PSA antibody (1:100, 10679-1-AP, Proteintech, China), anti-p63 antibody (1:100, D125020, Sangon Biotech, China), anti-SYP antibody (1:50, 60191-1-Ig, Proteintech, China), anti-Chromogranin-A antibody (1:5000, 60135-2-Ig, Proteintech, China). Secondary antibodies labeled with Alexa Fluor 488, 546, and 647 were purchased from Invitrogen (USA). After 2 h of secondary antibody incubation at room temperature, the cells were washed with PBS at least three times and subsequently stained with 5 µg/ml DAPI (Sigma-Aldrich, USA) for 30 min. Finally, the cells were washed once with PBS, ready for confocal microscopy. Organoids and the cryosections of Matrigel plugs were immunostained by similar protocols as above. Confocal microscopy was performed on a Leica SP8 confocal microscope.

Organoid formation assay

The cells were digested by accutase, centrifuged at 1200 rpm for 4 min, and mixed in Matrigel at a density of 5 × 103 cells per 100 µl of Matrigel in 24-well plates. The plates were then incubated in a 37 °C incubator for 30 min and added with 500 μl culture medium.

Cell transplantation in NOG mice

Male NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl (NOG) mice of 4–5 weeks were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd (China). The cells were dissociated with accutase, centrifuged at 1200 rpm for 4 min, mixed with Matrigel at a density of 1 × 106 cells per 200 µl Matrigel, and then injected into NOG mice subcutaneously. The Matrigel plugs were harvested after eight weeks for cryosection and immunostaining.

Transcriptomic sequencing and analysis

The cells were harvested in Trizol (Invitrogen, Cat#15596026, USA) and stored at − 80 °C. The mRNA library preparation and sequencing were performed on the DNBSEQ-T7 platform of Tsingke Biotechnology (China). The pair-end 150 base reads data were filtered with SOAPnuke (v1.5.2), mapped to the reference genome using HISAT2 (v2.0.4) and Bowtie2 (v2.2.5), and the expression levels of genes were calculated by StringTie (v2.1.2). KEGG pathway analysis was performed using the DAVID Bioinformatics Resources tools (https://david.ncifcrf.gov). The heatmap and bubble plots were drawn by SRplot (http://www.bioinformatics.com.cn) according to the gene expression in different samples.

Quantitative RT-PCR analysis

Total RNA was extracted in Trizol, and cDNA was prepared by an Evo M-MLV RT Mix Kit (Accurate Biotechnology, Cat#AG11728, China) according to the manufacturer's instructions. The experiment was carried out using the forward and reverse primers listed below, and levels of expression were normalized against GAPDH. The primer list:

Psca (Forward: 5′-GGACCAGCACAGTTGCTTTAC-3′ and Reverse: 5′-GTAGTTCTCCGAGTCATCCTCA-3′); Atg9b (Forward: 5′-ATGTACCCGAAGGACTCCG-3′ and Reverse: 5′-CATTCCGCTGATGATAGCTGT-3′); Aldh3a1 (Forward: 5′-TGGCAAAGACTCGTCAGACC-3′ and Reverse: 5′-AGTTCCAAGCACCTATGACAAG-3′); Krt13 (Forward: 5′- TCCAGAGCGGGACTACAGTG-3′ and Reverse: 5′-ATGATCCGGTTGTTGTCCGTG-3′); Ly6d (Forward: 5′-GGTTCCGAGGTCACACAATG-3′ and Reverse: 5′-CAGAGAGCCATAACAGTGAGC-3′); Ivl (Forward: 5′-ATGTCCCATCAACACACACTG-3′ and Reverse: 5′-TGGAGTTGGTTGCTTTGCTTG-3′); lIl33 (Forward: 5′- TCCAACTCCAAGATTTCCCCG-3′ and Reverse: 5′-CATGCAGTAGACATGGCAGAA-3′); Dsg3 (Forward: 5′- GAAGGTACAAACGTGAATGGGT-3′ and Reverse: 5′-ACTCCAGAAATGCGGTAGGTA-3′); Col17a1 (Forward: 5′-CAGTTACAGGAGAACGCACTC-3′ and Reverse: 5′-GGCGGGTCATGTGAGCTTT-3′).

Androgen deprivation and enzalutamide treatment

The cells were cultured and passaged in the media containing different concentrations of DHT and enzalutamide, including the following groups: 10 nM DHT, 1 nM DHT, 0.1 nM DHT, 0 nM DHT, 0.1 nM DHT with 1 μM enzalutamide, 0.1 nM DHT with 10 μM enzalutamide. The total treatment time was about one month.

Western blotting

The cells were washed with ice-cold PBS three times and lysed with RIPA lysis buffer (Sangon Biotech, China) with a protease inhibitors cocktail (Roche, China). The total protein content in the supernatant was measured by the BCA protein assay kit (Sangon Biotech, China) according to the manufacturer’s instruction. The samples were boiled with SDS-PAGE loading buffer (Solarbio, China). Twenty micrograms of protein was added to each lane, separated in 10% SDS-PAGE, and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, MA, USA) in a Trans-Blot apparatus (Tanon, China). 5% BSA diluted in TBS-T (0.05% Tween 20 in TBS) was used to block the membranes, and the primary antibodies with optimized concentrations, including AR (1:1000, ab108341, Abcam, USA), Actin (1:1000, D191048, Sangon Biotech, China), PSA (1:1000, 10679, Proteintech, China), were added to the membranes overnight at 4 °C. The membranes were incubated with the corresponding secondary antibodies conjugated with HRP (1:10000, D110011, Sangon Biotech, China) for 1 h at room temperature, and the bands were visualized by an enhanced chemiluminescence detection system.

Statistical analysis

All statistical analyses were conducted using GraphPad Prism 8 software. Data are presented as mean ± standard deviation. The significant differences were analyzed using ANOVA followed by Bonferroni post hoc tests. Statistical significance was defined as *p < 0.05, **p < 0.01, ***p < 0.001.

Results

Expand adult mouse CRIPSCs on 2D culture dishes in vitro

We isolated primary cells from the prostate tissue of adult WT and TRAMP mice by enzymatic digestion. We used a cyclic digestion method and harvested cell suspension every 10 min from the enzymatic solution. The primary cells contained single cells and small pieces of prostate tissues. The cells would migrate out of the small tissue pieces and populate the culture dishes. The initial passage (P0) had a mixture of cells with epithelial and mesenchymal morphologies (Fig. 1A and B). After the first passage, we noticed some islands of small epithelial cells (Fig. 1C and D). During the early four or five passages, there were many cells dying, and the overall cell proliferation was slow; thus, we passaged cells at a split ratio of 1:1 in this period. The small epithelial cells eventually dominated the population after four or five passages and proliferated rapidly with a doubling time of about one day in the following culture. During each passage, we froze most of the cells and only left 1/20 or less in a new culture dish. The freeze–thaw procedure did not affect the cell morphology, viability, or proliferation. These small epithelial cells referred to as CRIPSCs (Castration-Resistant Intermediate Prostate Stem Cells), can be cultured for more than six months in vitro, with a stable cell morphology (Fig. 1E–H). There was no apparent difference between WT and TRAMP CRIPSCs in the proliferation and morphology (Fig. 1).

Fig. 1
figure 1

Expansion of CRIPSCs from adult mice. Phase-contrast images of primary mouse prostate epithelial cells isolated from wild-type (WT) and TRAMP mice at primary passage (P0, 7 days, A and B), P1 (14 days) (C and D), P5 (2 months) (E and F), and P25 (6 months) (G and H). Arrows point to small epithelial cells. Arrowheads point to mesenchymal cells. Scale bars, 100 μm

Full size image

Characterization of the markers of mouse CRIPSCs

We first examined the luminal and basal cell markers of mouse CRIPSCs. In the primary (P0) cell culture, the epithelial cells expressed luminal markers CK8 and CK18, which disappeared after about five passages (P5) (Fig. 2A–D). The expanded mouse CRIPSCs of P5 expressed the epithelial marker E-cadherin, luminal markers AR and PSA, and basal markers CK5 and p63 (Fig. 2E–I). Sox2 was temporarily expressed in the cells of early passages; however, barely detected in the cells after P5 (Fig. 2J).

Fig. 2
figure 2

Marker expression of mouse CRIPSCs. The prostate epithelial cells isolated from WT mice at P0 (7 days) (A and B) and P5 (2 months) (C–J) were immunostained by the antibodies against CK8 (A and C), CK18 (B and D), AR (E), PSA (F), E-cadherin (G), CK5 (H), p63 (I), and Sox2 (J). DAPI-stained nuclei. Scale bars, 100 μm

Full size image

We performed transcriptomic sequencing on the prostate tissues and P5 WT CRIPSCs and found that the expanded WT CRIPSCs had upregulated signaling pathways related to cancer development and drug resistance (Fig. 3A). They lost CK8 (Krt8), CK18 (Krt18) and Pbsn; however, they still maintained other luminal cell markers, including Ar and Dsg4 [30], together with basal cell markers CK5 (Krt5), CK14 (Krt14), p63, and intermediate cell marker Ivl (Fig. 3B). WT mouse CRIPSCs also had higher expression of the genes related to stem cells (Psca, Atg9b, Sox2, Sox9), cell cycle (Cdk6), mammary luminal progenitor cells (Notch3 and Notch1) [31, 32], and cancers (Fig. 3B).

Fig. 3
figure 3

Gene expression profiles of mouse CRIPSCs. A KEGG pathway analysis. B Heatmap of the differentially expressed genes in prostate tissue and WT CRIPSCs. C qRT-PCR analysis of the expression of some genes in prostate tissue, the CRIPSCs cultured for 2 (P5) and 6 (P25) months in vitro, from WT and TRAMP mice. Data were presented as mean ± SD. Two-way ANOVA was performed on the data, followed by Bonferroni post hoc tests. “ns” = not significant. **p < 0.01. ***p < 0.001

Full size image

To further examine whether mouse CRIPSCs’ gene expression profiles will change or not during the long-term culture in vitro and the differences between WT and TRAMP cells, we performed qRT-PCR analysis. In the long-term culture for about six months, P25 WT and TRAMP CRIPSCs both expressed a high level of Psca (Fig. 3C). TRAMP CRIPSCs had a much higher expression of Atg9b, an autophagy gene responsible for stem cell maintenance [33], Ivl, a marker for intermediate prostate cells [34], and Krt13, a marker of prostate stem cells [35]. P25 TRAMP CRIPSCs also had upregulated genes related to cancer development and drug resistance, such as Aldh3a1, Ly6d, Il33, Dsg3, and Col17a1 (Fig. 3C).

Differentiation of mouse CRIPSCs

To test the differentiation potential, we mixed P25 WT and TRAMP CRIPSCs within Matrigel and found that they formed 3D organoids and grew into spheres with diameters of hundreds of micrometers during three weeks of culture (Fig. 4A and B). Immunofluorescence staining showed that the organoids expressed luminal markers: PSA, CK8, and CK18; basal cell markers: CK5 and p63; and lost Sox2 expression (Fig. 4C–E).

Fig. 4
figure 4

Organoid formation in vitro. A Phase-contrast images of the organoids formed by the CRIPSCs (P25, 6 months) derived from WT and TRAMP mice. B Quantification of organoid diameter. Data were presented as mean ± SD. Two-way ANOVA was performed on the data, followed by Bonferroni post hoc tests. ***p < 0.001. C–E, Immunofluorescence images of the organoids stained by the antibodies against CK8, CK18, PSA, p63, CK5, and Sox2. DAPI-stained nuclei. Scale bars, 100 μm

Full size image

To further investigate the differentiation potential in vivo, we injected WT and TRAMP CRIPSCs mixed in Matrigel into NOG mice subcutaneously. After eight weeks, the Matrigel plugs were harvested for cryosection and immunostaining. We found that only TRAMP CRIPSCs formed prostate ductal tissues in vivo and differentiated into prostate luminal epithelial cells (expressing CK8, CK18, AR, and PSA), basal cells (expressing CK5 and p63), and neuroendocrine cells (expressing CHGA and SYP) (Fig. 5).

Fig. 5
figure 5

Differentiation of mouse CRIPSCs in vivo. The CRIPSCs (P25, 6 months) isolated from TRAMP mice were transplanted into NOG mice for eight weeks, followed by cryosection and immunostaining (A–H). The antibodies included CK8 (A), CK18 (B), AR (C), PSA (D), CK5 (E), p63 (F), Chromogranin A (CHGA) (G), Synaptophysin (SYP) (H). DAPI-stained nuclei. Scale bars, 100 μm

Full size image

AR and PSA expression of CRIPSCs regulated by androgen deprivation and enzalutamide treatment

AR signaling pathway plays an essential role in prostate development and cancer. AR can be translocated from the cytoplasm to the nucleus upon binding to androgens. Our study expanded mouse CRIPSCs in the medium containing enough amounts of androgen, 10 nM DHT, which made AR located in the nucleus (Fig. 2E). To examine the reversibility of AR translocation, we cultured mouse CRIPSCs in the media supplemented with low concentrations (0, 0.1, and 1 nM) of DHT for 12 days and found that AR was located in the cytoplasm (Fig. 6A, C, and E). The addition of high (10 nM) DHT to the media in the last two days of culture resulted in AR translocation from the cytoplasm to the nucleus (Fig. 6B, D, and F). WT and TRAMP CRIPSCs had similar AR dynamics regulated by DHT.

Fig. 6
figure 6

AR translocation between the nucleus and cytoplasm. WT CRIPSCs (P25, 6 months) were cultured in the media supplemented with different concentrations of DHT for 12 days (A, 0 nM; C, 0.1 nM; E, 1 nM) or 10 days of low DHT followed by two days of 10 nM DHT (B, D, and F). DAPI-stained nuclei. Scale bars, 100 μm

Full size image

To mimic the clinical treatments for prostate cancer (ADT and enzalutamide), we cultured P25 mouse CRIPSCs in the media supplemented with different concentrations of DHT and enzalutamide for a month. The proliferation and cell morphology of WT and TRAMP CRIPSCs were not affected by androgen deprivation or enzalutamide treatment. The cells in all these different groups proliferated rapidly and were passaged every week. During each passage, most cells were frozen and only 1/20 or less cells were seeded to a new culture dish. By Western blotting, we found that androgen deprivation reduced the expression of AR in WT and TRAMP CRIPSCs. However, enzalutamide treatment promoted PSA expression in TRAMP CRIPSCs, while not in WT mice (Fig. 7). This result is similar to the clinical observations of CRPC recurrence.

Fig. 7
figure 7

AR and PSA regulation by androgen deprivation and enzalutamide treatment. Western blots and quantifications of AR and PSA of WT (A–C) and TRAMP (D–F) CRIPSCs (P25, 6 months) treated with different concentrations of DHT and enzalutamide (Enza) for one month. Data were presented as mean ± SD. One-way ANOVA was performed on the data, followed by Bonferroni post hoc tests. *p < 0.05. **p < 0.01. ***p < 0.001

Full size image

Discussion

Immunohistological studies and single-cell sequencing analysis show that most CRPCs have a luminal cell phenotype with high AR and PSA expression [1, 36]. Accumulating evidence proved the existence of castration-resistant luminal stem cells [14, 15, 17, 19]. However, expanding castration-resistant luminal cells with AR and PSA expression is challenging. Our study expanded CRIPSCs from WT and TRAMP mice, which expressed the epithelial marker E-cadherin, luminal markers (AR, PSA, and Dsg4), basal markers (CK5 and p63), and intermediate cell marker Ivl, implying they are an intermediate cell type. The CRIPSCs also expressed prostate stem cell antigen (Psca) and cyclin-dependent kinase 6 (Cdk6); the latter can associate with AR and enhance its transcriptional activity in prostate cancer cells [37]. This marker expression pattern is similar to the intermediate prostate epithelial cells. During embryonic development, there are many intermediate prostate epithelial cells co-expressing luminal (CK8) and basal (CK5) markers [38]. During postnatal development, the number of intermediate cells decreased [38], and there are still a small number (0.59%) of intermediate cells in the basal compartment of adult prostate tissue of mouse, rat, and human [39, 40]. However, there are few reports about culturing the intermediate cells in vitro.

In our study, the CRIPSCs can be cultured for more than six months with stable cell morphology. There were no apparent differences between WT and TRAMP CRIPSCs in proliferation and morphology after about P5. At the beginning of primary cell culture, there were mixtures of different cell types, including epithelial and mesenchymal cells. There were many cells dying, and the overall cell growth was slow compared to those of late passages. We noticed a transient expression of Sox2 in CRIPSCs at the early passages. Considering the critical roles of Sox2 in stem cells and prostate cancer development [41,42,43], we think Sox2 may contribute to establishing the stem cell colony at the first step.

Although there was no noticeable difference in the proliferation and morphology between WT and TRAMP CRIPSCs, the latter showed significantly higher expression of the genes related to cancer development and drug resistance (Fig. 3C). For example, Atg9b plays an essential role in stem cell maintenance and cancer development under the regulation of the Wnt/β-catenin signaling pathway [33]. In this study, the addition of Wnt/β-catenin signaling pathway agonist Chir99021 may be the reason for Atg9b upregulation. Wnt/β-catenin signaling pathway can also activate the intermediate prostate epithelial cell marker Ivl [34, 44]. Krt13 is a marker of prostate stem cells [35]. Aldehyde dehydrogenase (ALDH) family members, especially Aldh1 and Aldh3a1, are not only the markers of normal stem cells but also cancer stem cells and play essential roles in maintaining stem cell functions, including proliferation and resistance to cytotoxic drugs in some cancer types, including prostate cancer [45,46,47]. A recent single-cell sequencing study pointed out that Ly6d was a marker for castration-resistant prostate luminal cells and cancer development [48]. Il33 is related to cancer development, metastasis, and drug resistance [49,50,51,52]. Dsg3 plays an oncogenic role in head neck cancer [53]. Col17a1 plays an essential role in many malignancies by contributing to cancer cell proliferation and invasion [54].

During prostate development, epithelial–mesenchymal interaction is crucial for proper prostate tissue morphogenesis. Urogenital sinus mesenchyme (UGM) plays a determinant role in prostate tissue formation and can induce other epithelial cells, including bladder, vaginal, mammary, and skin epithelial cells, to form prostate tissue [38]. To examine the in vivo differentiation potential, researchers usually combined prostate stem cells with UGM cells before transplanting them into immunodeficient mice [38]. However, the mechanism underlying UGM induction of prostate tissue formation is not well understood. In this study, we transplanted CRIPSCs into NOG mice without UGM cells and found that WT CRIPSCs did not form prostate ducts, consistent with previous reports; on the contrary, TRAMP CRIPSCs formed well-developed prostate ductal structures with luminal, basal, and neuroendocrine cells. The genes related to stem cells, intermediate prostate cells, and cancer enriched in TRAMP CRIPSCs may contribute to their differentiation into prostate tissue without UGM induction. Further study is needed to investigate the mechanisms underlying the self-induction of TRAMP CRIPSCs.

AR is a core signaling pathway during prostate development, cancer formation, and drug resistance [1]. A cell culture model with AR and PSA expression and castration resistance will be valuable for the research of CRPC. Our immunostaining showed that androgen reversibly regulated AR translocation between the nucleus and cytoplasm (Fig. 6). We performed ADT and enzalutamide treatment on the cultured CRIPSCs for a month to mimic clinical therapies. These treatments downregulated AR expression in both WT and TRAMP CRIPSCs. However, TRAMP CRIPSCs acquired higher PSA expression upon enzalutamide treatment (Fig. 7). This result mimics the high PSA levels during the recurrence of CRPC to some extent.

Conclusions

Our study established a method for isolating and expanding mouse CRIPSCs on 2D culture dishes. Mouse CRIPSCs had markers of luminal and basal cells. TRAMP CRIPSCs can differentiate into prostate ductal tissues in vivo without recombination with UGM. Under enzalutamide treatment, TRAMP CRIPSCs acquired higher expression of PSA, similar to the situation of CRPC recurrence. Our method can be applied to human prostate cancer tissues for isolating and expanding patient-specific CRIPSCs, which will promote the development of precision medicine.

Availability of data and materials

The RNA-seq data reported in this paper have been deposited in the Genome Sequence Archive (GSA accession number: CRA007192) and are accessible at the URL: https://ngdc.cncb.ac.cn/gsa/browse/CRA007192.

Change history

Abbreviations

CRPC:

Castration-resistant prostate cancers

CRIPSCs:

Castration-resistant intermediate prostate stem cells

AR:

Androgen receptor

PSA:

Prostate-specific antigen

Psca:

Prostate stem cell antigen

Ivl:

Involucrin

UGM:

Urogenital sinus mesenchyme

WT:

Wild-type

ADT:

Androgen deprivation therapy

CARN:

Castration-resistant Nkx3.1-expressing cell

CARB:

Castration-resistant Bmi1-expressing cell

DHT:

Dihydrotestosterone

References

  1. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harbor Perspect Med. 2017;7(9):a030452.

    Google Scholar 

  2. Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018;9(1):3600.

    PubMed Central  PubMed  Google Scholar 

  3. Xie Q, Liu Y, Cai T, Horton C, Stefanson J, Wang ZA. Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun. 2017;8:14284.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354–73.

    PubMed Central  PubMed  Google Scholar 

  5. do Pazo C, Webster RM. The prostate cancer drug market. Nat Rev Drug Discov. 2021;20(9):663–4.

    CAS  PubMed  Google Scholar 

  6. Yu B, Liu Y, Luo H, Fu J, Li Y, Shao C. Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. J Biol Chem. 2021;296: 100276.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.

    CAS  PubMed  Google Scholar 

  8. Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naive, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. Urol Oncol. 2017;35(6):432–7.

    CAS  PubMed  Google Scholar 

  9. Li JJ, Shen MM. Prostate stem cells and cancer stem cells. Cold Spring Harbor Perspect Med. 2019;9(6):a030395.

    CAS  Google Scholar 

  10. Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, Mathis C, Cheng D, Stuart JM, Witte ON. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci USA. 2015;112(47):E6544-6552.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Wang BE, Wang X, Long JE, Eastham-Anderson J, Firestein R, Junttila MR. Castration-resistant Lgr5(+) cells are long-lived stem cells required for prostatic regeneration. Stem cell Rep. 2015;4(5):768–79.

    CAS  Google Scholar 

  12. Wang ZA, Toivanen R, Bergren SK, Chambon P, Shen MM. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep. 2014;8(5):1339–46.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Guo W, Li L, He J, Liu Z, Han M, Li F, Xia X, Zhang X, Zhu Y, Wei Y, et al. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nat Genet. 2020;52(9):908–18.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461(7263):495–500.

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Yoo YA, Roh M, Naseem AF, Lysy B, Desouki MM, Unno K, Abdulkadir SA. Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation. Nat Commun. 2016;7(1):12943.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Yoo YA, Vatapalli R, Lysy B, Mok H, Desouki MM, Abdulkadir SA. the role of castration-resistant Bmi1+Sox2+ cells in driving recurrence in prostate cancer. J Natl Cancer Inst. 2019;111(3):311–21.

    PubMed  Google Scholar 

  17. Kwon OJ, Zhang L, Xin L. Stem cell antigen-1 identifies a distinct androgen-independent murine prostatic luminal cell lineage with bipotent potential. Stem Cells. 2016;34(1):191–202.

    CAS  PubMed  Google Scholar 

  18. Ceder JA, Aalders TW, Schalken JA. Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. Stem Cell Res Ther. 2017;8(1):95.

    PubMed Central  PubMed  Google Scholar 

  19. Zhang D, Jeter C, Gong S, Tracz A, Lu Y, Shen J, Tang DG. Histone 2B-GFP label-retaining prostate luminal cells possess progenitor cell properties and are intrinsically resistant to castration. Stem cell Rep. 2018;10(1):228–42.

    CAS  Google Scholar 

  20. Zhang D, Lin K, Lu Y, Rycaj K, Zhong Y, Chao HP, Calhoun-Davis T, Shen J, Tang DG. Developing a novel two-dimensional culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate cancer. Stem Cells Transl Med. 2017;6(3):748–60.

    CAS  PubMed  Google Scholar 

  21. Hofner T, Eisen C, Klein C, Rigo-Watermeier T, Goeppinger SM, Jauch A, Schoell B, Vogel V, Noll E, Weichert W, et al. Defined conditions for the isolation and expansion of basal prostate progenitor cells of mouse and human origin. Stem cell Rep. 2015;4(3):503–18.

    Google Scholar 

  22. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–87.

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014;159(1):163–75.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Wang S, Gao D, Chen Y. The potential of organoids in urological cancer research. Nat Rev Urol. 2017;14(7):401–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  25. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362(6410):91–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Wang D, Wang E, Liu K, Xia CH, Li S, Gong X. Roles of TGFbeta and FGF signals during growth and differentiation of mouse lens epithelial cell in vitro. Sci Rep. 2017;7(1):7274.

    PubMed Central  PubMed  Google Scholar 

  27. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Muguruma K, Sasai Y. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25(6):681–6.

    CAS  PubMed  Google Scholar 

  28. Lee SH, Johnson DT, Luong R, Yu EJ, Cunha GR, Nusse R, Sun Z. Wnt/beta-catenin-responsive cells in prostatic development and regeneration. Stem Cells. 2015;33(11):3356–67.

    PubMed  Google Scholar 

  29. Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683–96.

    CAS  PubMed  Google Scholar 

  30. Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS ONE. 2014;9(6):e98786.

    PubMed Central  PubMed  Google Scholar 

  31. Lafkas D, Rodilla V, Huyghe M, Mourao L, Kiaris H, Fre S. Notch3 marks clonogenic mammary luminal progenitor cells in vivo. J Cell Biol. 2013;203(1):47–56.

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Rodilla V, Dasti A, Huyghe M, Lafkas D, Laurent C, Reyal F, Fre S. Luminal progenitors restrict their lineage potential during mammary gland development. PLoS Biol. 2015;13(2): e1002069.

    PubMed Central  PubMed  Google Scholar 

  33. Yun EJ, Kim S, Hsieh JT, Baek ST. Wnt/beta-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis. 2020;11(9):771.

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate. 2003;55(3):206–18.

    PubMed  Google Scholar 

  35. Hu WY, Hu DP, Xie L, Li Y, Majumdar S, Nonn L, Hu H, Shioda T, Prins GS. Isolation and functional interrogation of adult human prostate epithelial stem cells at single cell resolution. Stem cell Res. 2017;23:1–12.

    PubMed Central  PubMed  Google Scholar 

  36. Dong B, Miao J, Wang Y, Luo W, Ji Z, Lai H, Zhang M, Cheng X, Wang J, Fang Y, et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun Biol. 2020;3(1):778.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA. 2005;102(14):5156–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Toivanen R, Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017;144(8):1382–98.

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Wang Y, Hayward SW, Cao M, Thayer KA, Cunha GR. Cell differentiation lineage in the prostate. Differentiation. 2001;68(4):270–9.

    CAS  PubMed  Google Scholar 

  40. Xue Y, Smedts F, Debruyne FMJ, de la Rosette JJMCH, Schalken JA. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate. 1998;34(4):292–301.

    CAS  PubMed  Google Scholar 

  41. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  42. McAuley E, Moline D, VanOpstall C, Lamperis S, Brown R, Vander Griend DJ. Sox2 expression marks castration-resistant progenitor cells in the adult murine prostate. Stem Cells. 2019;37(5):690–700.

    CAS  PubMed  Google Scholar 

  43. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, et al. SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis. 2014;17(4):301–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU, et al. Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene. 2003;22(25):3875–87.

    CAS  PubMed  Google Scholar 

  45. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem cell Rev Rep. 2011;7(2):292–306.

    CAS  PubMed  Google Scholar 

  46. Gangavarapu KJ, Azabdaftari G, Morrison CD, Miller A, Foster BA, Huss WJ. Aldehyde dehydrogenase and ATP binding cassette transporter G2 (ABCG2) functional assays isolate different populations of prostate stem cells where ABCG2 function selects for cells with increased stem cell activity. Stem Cell Res Ther. 2013;4(5):132.

    PubMed Central  PubMed  Google Scholar 

  47. Yan J, De Melo J, Cutz JC, Aziz T, Tang D. Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. Br J Cancer. 2014;110(10):2593–603.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Barros-Silva JD, Linn DE, Steiner I, Guo G, Ali A, Pakula H, Ashton G, Peset I, Brown M, Clarke NW, et al. Single-cell analysis identifies LY6D as a marker linking castration-resistant prostate luminal cells to prostate progenitors and cancer. Cell Rep. 2018;25(12):3504-3518 e3506.

    CAS  PubMed Central  PubMed  Google Scholar 

  49. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134(7):1669–82.

    CAS  PubMed  Google Scholar 

  50. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz HJ, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA. 2015;112(19):E2487-2496.

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, Qin Q. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014;453(3):486–92.

    CAS  PubMed  Google Scholar 

  52. Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN, Shao JP, Ji H. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33(6):2746–52.

    CAS  PubMed  Google Scholar 

  53. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YC, Li YL, Chiou JF, et al. DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway. PLoS ONE. 2013;8(5): e64088.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Mao F, Li D, Xin Z, Du Y, Wang X, Xu P, Li Z, Qian J, Yao J. High expression of COL17A1 predicts poor prognosis and promotes the tumor progression via NF-kappaB pathway in pancreatic adenocarcinoma. J Oncol. 2020;2020:8868245.

    PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

This work was also supported by the Key Laboratory of Nucleic Acid Biology in Cardiovascular Disease, Shandong Province, and the International Research Centre for Non-coding RNAs and Translational Medicine, Qingdao. Thanks to Zhishang Chang, Qian Wen, Xuxia Song, and Bing Wang at the Laboratory of Biomedical Center, Qingdao University, for their technical help in confocal microscopy. We apologize to the scientists whose work was not cited due to space constraint.

Funding

This work was funded by the Natural Science Foundation of Shandong Province (No. ZR2019LZL001 and ZR2020MC071), the National Nature Science Foundation of China (No. 32101020), and the People’s Livelihood Science and Technology Project of Qingdao (No. 20-3-4-41-nsh and 19-6-1-44-nsh).

Author information

Author notes

  1. Yalan Xu and Jie Mu contributed equally to this work.

Authors and Affiliations

  1. Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Medical College, Qingdao University, Qingdao, 266021, China

    Yalan Xu, Zhixia Zhou, Yu Leng, Yali Yu, Xiuyue Song, Jing Li & Dong Wang

  2. School of Basic Medicine, Qingdao University, Qingdao, 266021, China

    Yalan Xu, Yu Leng, Yali Yu & Xiuyue Song

  3. College of Life Sciences, and School of Pharmacy, Medical College, Qingdao University, 308 Ningxia Road, Qingdao, 266071, China

    Jie Mu & Aihua Liu

  4. Department of Urology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, 266011, China

    Hai Zhu

Authors
  1. Yalan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhixia Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Leng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yali Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiuyue Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aihua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hai Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.W., H.Z., and J.L. conceived and designed the study. Y.X., J.M., Z.Z., Y.L., Y.Y., and X.S. performed the experiments. J.M. performed the qRT-PCR analysis. Y.X. performed WB. Y.X., J.M., A.L. D.W., H.Z., and J.L. analyzed transcriptomic data, Y.X., D.W., H.Z., and J.L. wrote the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Hai Zhu, Jing Li or Dong Wang.

Ethics declarations

Ethics approval and consent to participate

All animal procedures were performed according to the Ministry of Science and Technology guide for laboratory animal care and use and approved by the animal care and use committee of Qingdao University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Y., Mu, J., Zhou, Z. et al. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro. Stem Cell Res Ther 13, 299 (2022). https://doi.org/10.1186/s13287-022-02978-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13287-022-02978-x

Keywords

  • castration-resistant prostate cancer
  • Stem cell
  • Intermediate cell
  • Androgen receptor
  • Prostate-specific antigen
  • Androgen deprivation
  • Enzalutamide

Stem Cell Research & Therapy

ISSN: 1757-6512